Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial (NCT05006482)

🧪 Interventions in This Study

• Best Practice (OTHER)
• Comprehensive Geriatric Assessment (OTHER)
• Educational Intervention (OTHER)
• Exercise Intervention (OTHER)
• Questionnaire Administration (OTHER)
• Tailored Intervention (PROCEDURE)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. PRACTICE CRITERIA: Participating practice clusters will be required to identify one (or more) oncologist and/or advanced practice practitioner (APPs; i.e., nurse practitioners, or physician assistants) as part of study eligibility. If another clinician is interested in participating, please contact University of Rochester Cancer Center (URCC) National Cancer Institute Community Oncology Research Program (NCORP) Research Base (RB) for approval
2. Oncologists/APPs/other clinicians must be licensed to practice
3. Oncologists/APPs/other clinicians must not have a plan to leave or retire from the NCORP practice within one year of enrolling into the study
4. PRACTICE CRITERIA: Support/buy-in from oncology physicians and/or APPs and/or other clinicians who are willing to participate in training and study procedures and enroll cancer survivors
5. ENTRY CRITERIA FOR ONCOLOGY PHYSICIANS/APPS/OTHER CLINICIANS: Oncology physicians/APPs/other clinicians must work at a participating site with no plans to leave that practice or retire within one year of enrollment into the study. We do not require that any or all oncology physicians and/or APPs at a practice setting agree to participate. Only one clinician is required for the practice cluster to be eligible. If another clinician (other than oncology physician or APP) is interested in participating, please contact URCC NCORP RB for approval
6. CANCER SURVIVORS: 65 years or older
7. CANCER SURVIVORS: Have completed or will have completed curative-intent treatment (e.g., surgery, chemotherapy, chemotherapy with radiation) for any solid tumor or lymphoma malignancy in last 6 months. If the survivor is receiving curative-intent chemotherapy, run-in study procedures can occur during the last 6 weeks of chemotherapy.
8. Cancer survivors who will receive or are receiving other treatments (e.g., hormonal treatment, monoclonal antibodies, immunotherapy, radiation) are eligible
9. For patients receiving neoadjuvant chemotherapy for curative intent, the run-in and baseline procedures can occur before or after surgery. Patients should be enrolled within 6 months from the end of surgery
10. CANCER SURVIVORS: Be willing and able to come in for study visits or willing to undergo informed consent and assessments remotely via tele-health visits
11. CANCER SURVIVORS: Be willing and able to provide informed consent and must sign consent in-person or remotely if it is not convenient or feasible to provide informed consent in-person
12. CANCER SURVIVORS: Speak and understand English and/or Spanish. Spanish-speaking cancer survivors are eligible as long as there are appropriate resources in place for completion of study procedures at the practice site. Registration for Spanish-speaking cancer survivors must be approved by the URCC NCORP Research Base after a phone call to determine the feasibility for the practice to enroll a Spanish-speaking participant

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (45 Sites)

Showing the first 25 of 45 sites.

• Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
• Kaiser Permanente-Fremont — Fremont, California
• Kaiser Permanente-San Francisco — San Francisco, California
• Helen F Graham Cancer Center — Newark, Delaware
• Medical Oncology Hematology Consultants PA — Newark, Delaware
• Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
• Straub Clinic and Hospital — Honolulu, Hawaii
• Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
• Tripler Army Medical Center — Honolulu, Hawaii
• Hawaii Cancer Care - Westridge — ‘Aiea, Hawaii
• Pali Momi Medical Center — ‘Aiea, Hawaii
• OSF Saint Anthony's Health Center — Alton, Illinois
• Fairview Southdale Hospital — Edina, Minnesota
• Hennepin County Medical Center — Minneapolis, Minnesota
• Monticello Cancer Center — Monticello, Minnesota
• Park Nicollet Clinic - Saint Louis Park — Saint Louis Park, Minnesota
• Regions Hospital — Saint Paul, Minnesota
• Lakeview Hospital — Stillwater, Minnesota
• Rice Memorial Hospital — Willmar, Minnesota
• Minnesota Oncology Hematology PA-Woodbury — Woodbury, Minnesota
• Lake Regional Hospital — Osage Beach, Missouri
• Noyes Memorial Hospital/Myers Cancer Center — Dansville, New York
• Northwell Health/Center for Advanced Medicine — Lake Success, New York
• Highland Hospital — Rochester, New York
• Pluta Cancer Center — Rochester, New York

📞 Contact the Study Coordinator

Phone: (800) 338-2948

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lymphoma

• A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Aurora, Colorado
• Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy — Salt Lake City, Utah
• TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas — Palo Alto, California
• A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients — New York, New York
• Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma — Rochester, Minnesota
• A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — La Jolla, California

Explore by condition: All Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.